Clinical and Experimental Obstetrics & Gynecology (Jul 2022)

Advances in Cytoreductive Surgery and Combination Therapy for Ovarian Cancer

  • Xiaolan Lv,
  • Wenyong Chen,
  • Tao Qi,
  • Yanling Ding

DOI
https://doi.org/10.31083/j.ceog4907166
Journal volume & issue
Vol. 49, no. 7
p. 166

Abstract

Read online

Objective: Ovarian carcinoma is a malignant tumor with the highest mortality of any cancer occurring in female reproductive system. Cytoreductive surgery is the main treatment for ovarian cancer and has markedly improved. Mechanism: This article discusses the evolution and development of ovarian cancer cytoreductive surgery (CRS), including classical standard tumor cell reduction, visceral-peritoneal debulking (VPD) and ultra-radical cytoreduction (URC). Findings in Brief: we reviewed CRS in combination with radiotherapy, chemotherapy and immunotherapy for ovarian cancer (OC). Finally, we discussed the opportunity and challenges of ROC therapeutic. Conclusions: This study reveals that CRS and combination therapy can help clinicians to find the optimum treatment for ovarian cancer (OC).

Keywords